Quick Answer
HALOZYME THERAPEUTICS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $1.40 billion for the year ending 2025.
- HALOZYME THERAPEUTICS, INC. showed an increase of +37.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $30.87 million | Q2 2018: $35.20 million | Q3 2018: $25.56 million | Q1 2019: $56.95 million | Q2 2019: $39.15 million | Q3 2019: $46.23 million | Q1 2020: $25.35 million | Q2 2020: $55.22 million | Q3 2020: $65.32 million | Q1 2021: $89.02 million | Q2 2021: $136.46 million | Q3 2021: $115.83 million | Q1 2022: $117.28 million | Q2 2022: $152.37 million | Q3 2022: $208.98 million | Q1 2023: $162.14 million | Q2 2023: $221.04 million | Q3 2023: $216.03 million | Q1 2024: $195.88 million | Q2 2024: $231.35 million | Q3 2024: $290.08 million | Q1 2025: $264.86 million | Q2 2025: $325.72 million | Q3 2025: $354.26 million.
- Over the full 9 years of available data (2017 to 2025), HALOZYME THERAPEUTICS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 341.1%.
- Historical annual values: Fiscal year 2025: $1.40 billion | Fiscal year 2024: $1.02 billion | Fiscal year 2023: $829.25 million | Fiscal year 2022: $660.12 million | Fiscal year 2021: $443.31 million | Fiscal year 2020: $267.59 million | Fiscal year 2019: $195.99 million | Fiscal year 2018: $151.86 million | Fiscal year 2017: $316.61 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: